Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

From Adelaide to San Francisco, the biotechnology landscape is shifting – and, in some cases, straining under the weight of ...

The business may not be as strong as its performance this year suggests.

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...